The 27th Annual Meeting will take place May 14–17, 2014, at the historic Palmer House Hilton hotel in downtown Chicago, a short stroll from the world-acclaimed Art Institute of Chicago, the Adler and Sullivan’s Auditorium Theater, the Lyric Opera of Chicago, the Goodman Theater, and exciting Millennium Park.

Presidential Symposium: Future of Pediatric Hematology
The Presidential Symposium will focus on the future of pediatric hematology, emerging gene therapies, the pathophysiology of hemoglobinopathies, and fetal hemoglobin. You will not want to miss this insightful and thought-provoking session presented by Katherine A. High, MD; Elliot P. Vichinsky, MD; and Stuart H. Orkin, MD, who are luminaries in the field. See page 11 for further details.

Content-Rich Meeting Program
The program for the meeting includes an exceptional selection of 11 symposia and 12 workshops all designed to bring you current science, clinical updates, and contemporary controversies in pediatric hematology/oncology. Symposia program topics include
- Updates in Lymphatic Anomalies for the Hematologist/Oncologist
- Sickle Cell Disease—Saving the Brain and Treating the Pain
- Update on Coagulation and Platelet Testing—New Methods to Evaluate Hemostatic Function
- Out of Body Experiences: Extracorporeal Therapies in Pediatric Hematology
- When Less Is More: Update on Reduced Intensity/Nonmyeloablative Stem Cell Transplant Conditioning Regimens in Malignant and Nonmalignant Disorders
- Personalized Care for Pediatric Brain Tumors: Fact or Fiction?
- Tumor Heterogeneity
- Bone Health in Pediatric Hematology/Oncology
- Genomics and Personalized Medicine in Childhood Cancer.

Pediatric Blood and Marrow Transplant Consortium
For the second year, the Pediatric Blood and Marrow Transplant Consortium (PBMTC) will hold its meeting in affiliation with the ASPHO meeting. The PBMTC program will be presented on Wednesday, May 14, also at the Palmer House Hilton. Educational program details are available on page 6. A discount is available for those registering for both the PBMTC and ASPHO meetings.

Maintenance of Certification
ASPHO will again present an opportunity for attendees to earn Part 2 points toward Maintenance of Certification (MOC) by offering an American Board of Pediatrics (ABP) Lifelong Learning and Self-Assessment Module. The MOC program, scheduled for Saturday morning, is intended for those who are enrolled in the MOC process and would like to earn 10 MOC activity points and 3 AMA PRA Category 1 Credits™. The MOC Learning Session will be conducted in an interactive group setting and led by authors or experts in the field.

“A very well-organized conference. I really enjoyed the mix of clinical practice and basic science.”
—2013 Meeting Attendee
New Meeting Schedule

In response to participant feedback, this year’s educational program schedule features a relaxed morning start time of 8 am or later each day (some ancillary events are scheduled during breakfast), and more time is built into the program to allow for networking and socializing. Note these changes will not affect the total available number of continuing medical education (CME) credits offered to attendees.

We hope to see you in Chicago!

Objectives

- Comprehend new information in pediatric hematology/oncology, including the latest in basic and clinical research.
- Apply knowledge gained in all areas of pediatric hematology/oncology investigation and practice.
- Assemble a network of professional colleagues with whom you can solve problems, share experiences, and provide mutual professional support.

Specifically, at the end of the meeting, we expect participants will be better able to
- discuss the biological basis of tumor heterogeneity and develop paradigms of treatment
- describe strategies for incorporation of genetic information into clinical trials for children with brain tumors
- describe current nomenclature and risk stratification for lymphatic anomalies
- identify the prevalence, investigation, and management of post-thrombotic syndrome as well as assessing and selecting various adjunctive therapies available for patients with hemostatic and thrombotic disorders
- describe the various avenues toward scholarship in education and how to lead change and implement new visions
- discuss supportive care options in pediatric hematology/oncology.

Program details begin on page 8.

“It was a great meeting! I left feeling so excited about my career and inspired to make positive changes in our organization!”

—2013 Meeting Attendee
Thank You, ASPHO Program Committee

Douglas K. Graham, MD PhD, Chair
University of Colorado Denver
Aurora, CO

Daniel S. Wechsler, MD PhD, Vice Chair
Duke University Medical Center
Durham, NC

Jorge DiPaola, MD, Past Chair
University of Colorado Denver
Aurora, CO

Oussama Abla, MD
Hospital for Sick Children
Toronto, ON, Canada

Denise M. Adams, MD
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Patrick Brown, MD
Johns Hopkins Hospital
Baltimore, MD

Valerie Brown, MD PhD
The Pennsylvania State University College of Medicine
Hershey, PA

Michael Callaghan, MD
Children’s Hospital of Michigan
Detroit, MI

Jacqueline N. Casillas, MD MSHS
David Geffen School of Medicine at UCLA
Los Angeles, CA

Sinisa Dovat, MD PhD
The Pennsylvania State University College of Medicine
Hershey, PA

Karen E. Effinger, MD MS
Stanford University
Palo Alto, CA

Roger H. Giller, MD (PBMTC Liaison)
Children’s Hospital Colorado
Aurora, CO

Sumit Gupta, MD
The Hospital for Sick Children
Toronto, ON, Canada

Caroline A. Hastings, MD
Children’s Hospital of Oakland
Oakland, CA

Alex Kentsis, MD PhD
Memorial Sloan-Kettering Cancer Center
New York, NY

Neyssa Marina, MD
Stanford University School of Medicine
Palo Alto, CA

Kate A. Mazur, MSN RN CPNP
Baylor College of Medicine
Houston, TX

Emily Riehm Meier, MD
Children’s National Medical Center
Washington, DC

Donald William Parsons, MD PhD
Baylor College of Medicine
Houston, TX

Cameron Trenor, MD
Boston Children’s Hospital
Boston, MA

Lisa Triche, MSN RN CPNP
University of Texas MD Anderson Cancer Center
Houston, TX

Sarah Vaiselbuh, MD
Staten Island University Hospital
Staten Island, NY

Michael Wang, MD
University of Colorado Denver
Aurora, CO

Donald L. Yee, MD MS
Baylor College of Medicine
Houston, TX

Peter Zage, MD PhD
Texas Children’s Hospital
Houston, TX

Patrick A. Zweidler-McKay, MD PhD
University of Texas MD Anderson Cancer Center
Houston, TX

The American Society of Pediatric Hematology/Oncology’s 27th Annual Meeting will offer continuing medical education (CME) credit. Credit will be awarded for those sessions attended and evaluated. A certificate will be issued upon receipt of submission of the evaluation.

The American Society of Pediatric Hematology/Oncology is accredited by the Accreditation Council for Continuing Medical Education to provide CME for physicians.

The American Society of Pediatric Hematology/Oncology designates this live activity for a maximum of 23.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ASPFO offers its meeting evaluation in an online format. Meeting registrants can access the evaluation by visiting the ASPHO website, www.asphomeeting.org, and clicking on the Evaluation Form link located on the home page. The online evaluation may be completed during the meeting or after attendees have returned home. Participants will receive their certificate immediately when they submit their evaluations online. We encourage all attendees to complete this evaluation regardless of whether they are seeking CME credits. For more information, visit www.asphomeeting.org or call 847.375.4716.

Disclosure
It is the policy of ASPHO that the planners, faculty, and providers disclose the existence of any significant financial interests or other relationships they and/or their spouse/partner may have with the manufacturer(s) of any commercial product(s) or services relating to the topics presented in the educational activity. ASPHO requires disclosure of the intent to discuss unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose. It is the responsibility of the Certification and Continuing Education Committee to review potential conflicts of interest as submitted in the disclosure form and resolve such conflicts. Resolving the conflict ensures that the content of the activity is aligned with the interests of the public. Detailed disclosure information will be published in course materials. Learners will also be informed when no relevant financial relationships exist.

Disclaimer
The material presented in this activity represents the opinion of the speakers and not necessarily the views of ASPHO.

Annual Meeting DVDs
ASPFO will offer annual meeting attendees session recordings on DVD. Conference attendees will have the opportunity to purchase a DVD when they register for the meeting or in Chicago, May 15–17, 2014, at a special discounted rate of $50. After May 17, DVDs will be sold for $99.

With these DVDs, you will have convenient access to session recordings without long download times or access codes. Take advantage of this special limited offer when you register or onsite in Chicago.
## ASPHO Education Schedule at a Glance

### Wednesday, May 14

**8:30 am–Noon**

**Training Program Directors’ Milestone, Competency, and EPA Workshop**
Advance registration is required.

**1–2 pm**

**Vascular Anomalies Special Interest Group**
Advance registration is required.

**2:15–3:45 pm**

**Concurrent Workshops**
(W01) Systems to Quantify Nonclinical Faculty Activities and to Reward Faculty for Nonclinical Accomplishments

**4–5:30 pm**

**Concurrent Workshops**
(W02) Hot Topics in Policy Advocacy for Pediatric Hematologists/Oncologists

**5:45–7:45 pm**

**Symposia**
(S01) Updates in Lymphatic Anomalies for the Hematologist/Oncologist
(S02) Sickle Cell Disease—Saving the Brain and Treating the Pain

### Thursday, May 15

**8–9:30 am**

**Concurrent Workshops**
(W05) Missed Opportunities for Scholarship in Education
(W06) Walking the Line: Ethical Decision Making with Families at the Fringes
(W07) Decreasing Time to Antibiotic Delivery in Febrile Neutropenic Patients Through Quality Improvement Methods in Your Home Institution

**9:45 am–Noon**

**Presidential Symposium and State of the Society**
(S03) The Future of Pediatric Hematology

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15–1:15 pm</td>
<td><strong>Non-CME Luncheon Session</strong> Topic: Immunotherapy Seating is limited. Refer to the ASPHO website for details.</td>
</tr>
<tr>
<td>12:15–1:30 pm</td>
<td><strong>(L01) Early Career Roundtable Workshop Luncheon</strong></td>
</tr>
<tr>
<td>1:45–3:45 pm</td>
<td><strong>Symposia</strong> (S04) Tumor Heterogeneity: Biology and Therapy (S05) When Less Is More: Update on Reduced Intensity/Nonmyeloablative Stem Cell Transplant Conditioning Regimens in Malignant and Nonmalignant Disorders</td>
</tr>
</tbody>
</table>

### Friday, May 16

**7 am–4:45 pm**

**Early Career Coffee Corner**

**7:30–9 am**

**Diversity Special Interest Group**
Advance registration is required.

**8–9 am**

**Continental Breakfast in Exhibit Hall**

**9–11 am**

**Symposia**
(S06) Genomics and Personalized Medicine in Childhood Cancer
(S07) Update on Coagulation and Platelet Testing

**11–11:30 am**

**Break in Exhibit Hall**
Passport drawing 11:15 am

**11:30 am–1 pm**

**Concurrent Workshops**
(W08) What’s All the Buzz About Targeted Immunotherapies for B-Cell Malignancies? (W09) Neonatal Thrombosis: An Insight on Development, Management, and Outcomes (W10) Late Career Transitions in Pediatric Hematology/Oncology

**1–2 pm**

**Author-Attended Poster Session B** Even-numbered posters

**1–2:30 pm**

**Lunch in Exhibit Hall**
Exhibits and Posters
Final passport drawing 1:30 pm

### Saturday, May 17

**7–9 am**

**Maintenance of Certification (MOC) Learning Session**
Advance registration is required.

**Palliative Care Special Interest Group**
Advance registration is required.

**9–10:30 am**

**Concurrent Workshops**

**10:45 am–12:45 pm**

**Symposia**
(S10) Personalized Care for Pediatric Brain Tumors: Fact or Fiction?
(S11) Out of Body Experiences: Extracorporeal Therapies in Pediatric Hematology

---

*For more information on corporate forum symposia, see page 19. Program details begin on page 8. © early career opportunity*
The Pediatric Blood and Marrow Transplant Consortium (PBMTC) Educational Program will include a day focused on pediatric bone marrow transplant (BMT) preceding the ASPHO Annual Meeting. The sessions will invigorate the field of pediatric BMT and encourage physicians to learn more about a rapidly advancing field about which they may have limited knowledge. This day focused on pediatric BMT also will allow pediatric hematology/oncology practitioners who do a small amount of pediatric BMT to attend a meeting to which they wouldn’t normally have access.

To register for just the PBMTC program, go to www.pbmtc.org/PBMTCMeetings/PBMTCASPHOMeeting/default.aspx. Contact Laura Hancock with any questions at lhancock@pbmtc.org or 626.241.1619. Discounted registration is offered for those attending both the PBMTC and ASPHO meetings. See the registration form for details.

**Wednesday, May 14**

7:45–8 am  
Introduction

8–9:30 am  
**(B01) Plenary Session I**  
New Frontiers in Hematopoietic Cell Transplant for Acute Myeloid Leukemia  
John Horan, MD (Moderator); Soheil Meshinchi, MD PhD; John P. Perentesis, MD FAAP

9:30–10:30 am  
**(B02) Plenary Session II**  
Optimization of Donor Selection  
Ann E. Woolfrey, MD (Moderator); Marie Bleakley, MD

10:45 am–12:15 pm  
**(B03) Plenary Session III**  
New Frontiers in GVHD: Strategies for GVHD Prevention and Potential Application of Biomarkers in Clinical Practice  
Carrie Kitho, MD (Moderator); John Levine, MD MS; Leslie Kean, MD PhD

12:15–1:15 pm  
Lunch and Concurrent Workshops  
**(B04) Workshop I**  
Career Development in Pediatric Blood and Marrow Transplant  
Eneida Nemecek, MD (Moderator); Alisa B. Lee Sherick, MD  
**(B05) Workshop II**  
Mid-Level Practitioner Interest Group  
Brandon Nuechterlein, PA-C (Moderator); Vicki L. Fisher, MSN RN CNP CPON

1:30–3 pm  
**(B06) Workshop III**  
Impact of KIR and HLA Genotypes on Transplant Outcome  
Katherine Hsu, MD PhD (Moderator); Wing Leung, MD PhD

3–4:30 pm  
**(B07) Plenary Session IV**  
Diagnosis, Newborn Screening, and Transplantation of Patients with Severe Combined Immunodeficiency  
Sung-Yun Pai, MD (Moderator); Christopher C. Dvorak, MD; Jennifer Puck, MD

4:45–6:15 pm  
**(B08) Plenary Session V**  
Infectious Complications of HSCT: New Modalities for Diagnosis and Treatment of Viral Diseases  
Janet Englund, MD (Moderator); Patricia Flynn, MD

6:15–7:15 pm  
Author-Attended Poster Session and Reception

To view specific session information, visit www.pbmtc.com.

“First ASPHO meeting I attended. It was excellent!”  
—2013 Meeting Attendee
Pediatric Blood and Marrow Transplant Consortium Educational Program
Held in Conjunction with ASPHO Annual Meeting

Faculty
Marie Bleakley, MD
Fred Hutchinson Cancer Research Center
Seattle, WA

Christopher C. Dvorak, MD
University of California, San Francisco
San Francisco, CA

Janet Englund, MD
Seattle Children’s Hospital
Seattle, WA

Vicki L. Fisher, MSN RN CNP CPON
Jazz Pharmaceuticals
Medina, OH

Patricia Flynn, MD
St. Jude Children’s Research Hospital
Memphis, TN

Roger H. Giller, MD
Children’s Hospital Colorado
Aurora, CO

John Horan, MD
Emory University Aflac Cancer & Blood Disorders Center
Atlanta, GA

Katherine Hsu, MD PhD
Memorial Sloan-Kettering Cancer Center
New York, NY

Leslie Kean, MD PhD
Seattle Children’s Hospital
Seattle, WA

Carrie Kitko, MD
C. S. Mott Children’s Hospital
Ann Arbor, MI

Alisa B. Lee Sherick, MD
University of Colorado
Denver, CO

Wing Leung, MD PhD
St. Jude Children’s Research Hospital
Memphis, TN

John Levine, MD MS
C. S. Mott Children’s Hospital
Ann Arbor, MI

Paul L. Martin, MD PhD
Duke University
Durham, NC

Soheil Meshinchi, MD PhD
Fred Hutchinson Cancer Research Center
Seattle, WA

Eneida Nemecek, MD
Oregon Health and Science University
Portland, OR

Brandon Nuechterlein, PA-C
Children’s Hospital Colorado
Aurora, CO

Sung-Yun Pai, MD
Dana-Farber Cancer Institute
Boston, MA

John P. Perentesis, MD FAAP
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Jennifer Puck, MD
University of California, San Francisco
San Francisco, CA

Vanderson Rocha, MD PhD
Churchill Hospital
Oxford, UK

Ann Woolfrey, MD
Fred Hutchinson Cancer Research Center
Seattle, WA

Planning Committee
Roger H. Giller, MD, Chair
Children’s Hospital Colorado
Aurora, CO

Mitchell S. Cairo, MD
New York Medical College
Valhalla, NY

Janet Englund, MD
Seattle Children’s Hospital
Seattle, WA

John Horan, MD
Emory University Aflac Cancer & Blood Disorders Center
Atlanta, GA

Katherine Hsu, MD PhD
Memorial Sloan-Kettering Cancer Center
New York, NY

Carrie Kitko, MD
C. S. Mott Children’s Hospital
Ann Arbor, MI

Eneida Nemecek, MD
Oregon Health and Science University
Portland, OR

Michael Pulsipher, MD
Primary Children’s Medical Center/University of Utah
Salt Lake City, UT

Ann E. Woolfrey, MD
Fred Hutchinson Cancer Research Center
Seattle, WA

Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the American Society of Pediatric Hematology/Oncology and the Pediatric Blood and Marrow Transplant Consortium. The American Society of Pediatric Hematology/Oncology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. American Society of Pediatric Hematology/Oncology designates this live activity for a maximum of 9.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure
It is the policy of ASPHO that the planners and faculty disclose the existence of any significant financial interest or other relationships they and/or their spouse or partner may have with the manufacturer(s) of any commercial product(s) or services relating to the topics presented in the educational activity. ASPHO requires disclosure of the intent to discuss unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose. It is the responsibility of the Certification and Continuing Education Committee to review potential conflicts of interest as submitted in the disclosure form and resolve such conflicts. Resolving the conflict ensures that the content of the activity is aligned with the interests of the public. Detailed disclosure information is included in this session information. Learners will also be informed when no relevant financial relationships exist.

Disclaimer
The materials presented in this activity represent the opinions of the speakers and not necessarily the views of ASPHO or PBMTC.
Wednesday, May 14, 2014

8:30 am–Noon

Training Program Directors’ Milestone, Competency, and EPA Workshop

Don’t Panic, We Already Did That for You!
Patrick Leavey, MD; Mark Atlas, MD; Rima F. Jubran, MD MPH; Jennifer C. Kesselheim, MD MEd

This workshop is open to fellowship program directors and all attendees who are looking for a broad review of entrustable professional activities (EPAs) and milestones, the Next Accreditation System (NAS), evaluations, EPAs specifically for pediatric hematology/oncology, mapping, and curriculum planning. Register now to implement the NAS without too much stress!

Advance registration required.

1–2 pm

Vascular Anomalies Special Interest Group
Cochairs: Denise M. Adams, MD; Cameron Trenor, MD; Leonardo R. Brandao, MD MSc

The Vascular Anomalies Special Interest Group will hold a working group meeting to discuss:
1. the treatment of complicated lymphatic anomalies
2. an update on lymphatic registry at Boston Children’s/ expansion to other sites
3. the protocol for at-risk vascular malformation patients with baseline coagulopathy.

Part of the meeting will be spent reviewing complicated patients. Further information about selection of these cases will be forwarded prior to the meeting.

Advance registration is required.

2:15–3:45 pm

Concurrent Workshops

(W01) Systems to Quantify Nonclinical Faculty Activities and to Reward Faculty for Nonclinical Accomplishments
Moderator: Jeffrey D. Hord, MD

Pediatric hematologists/oncologists are expected to carry out a wide range of activities in addition to providing clinical care. They are asked to educate trainees, conduct research, administer over operations, and work to improve the quality and safety of care. ASPHO surveys have shown that most programs have relative value units-based incentive compensation plans to track and quantify clinical work but very few have detailed systems to quantify nonclinical activities and reward those who are successful in nonclinical areas. Among responders to the 2013 ASPHO Workforce Survey, a few programs reported that they have well-established incentive compensation plans that include nonclinical accomplishments. Faculty members from three such programs will describe the systems used at their centers and answer questions from the audience. This should provide attendees a basis for developing a system that will fit their centers.

Tracking Nonclinical Faculty Activity at Brown
Anjulika Chawla, MD

Tracking Nonclinical Faculty Activity at Stanford
Sheri L. Spunt, MD

Tracking Nonclinical Faculty Activity at Johns Hopkins
Ido Paz-Priel, MD

(W02) Hot Topics in Policy Advocacy for Pediatric Hematologists/Oncologists
Naomi L. Luban, MD; Mark Del Monte, JD; Invited: Gregory Reaman, MD; Yoram Unguru, MD

The session will address hot topics in public policy advocacy relevant to pediatric hematologists/oncologists and the patients they serve and provide an overview of the political and health policy environment in Washington, DC. The session will also include an in-depth review of policy issues, focusing on implications for the practitioner and offering practical advice for ASPHO members interested in becoming more involved in policy advocacy at the state and national levels.

4–5:30 pm

Concurrent Workshops

(W03) Do You REALLY Want Fries with That? Critical Mini-Reviews of Adjunctive Therapies in Pediatric Hemostasis/Thrombosis
Moderator: Donald L. Yee, MD MS

Hemostatic and thrombotic disorders are among the most common topics suggested by previous ASPHO meeting attendees for future educational sessions. Management of such disorders often focuses on core approaches such as factor replacement or anticoagulation, respectively. However, additional treatment adjuncts are sometimes used to supplement or support the more primary therapies through parallel or compensatory hemostatic pathways (e.g., recombinant factor VIII). Other interventions may be more centrally directed at the pathologic defect or problem but are not widely regarded as core treatments (e.g., antithrombin concentrate, fresh frozen plasma, caval filters). Given the relative dearth of attention directed at these adjunctive therapies, many pediatric hematologists/oncologists lack a firm grasp of available evidence pertinent to their use and associated risks in pediatrics. This therapy-centered, case-based, interactive session will equip participants with important knowledge and skills regarding these sometimes esoteric adjuncts using a focused, mini-review approach.

Introduction and Mini-Reviews: Antithrombin Concentrate
Donald L. Yee, MD MS

Mini-Reviews: Recombinant Factor VIIa
Riten Kumar, MD MSc

Mini-Reviews: Fresh Frozen Plasma
John Puetz, MD
Mini-Reviews: IVC Filters  
Char Witmer, MD MSCE

(W04) Management of Recurrent Sarcoma in Children and Adolescents  
Moderator: Nicholas D. Yeager, MD  
Despite significant advances in many areas of pediatric oncology, the long-term prognosis for patients with recurrent sarcoma remains poor. Survival rates for patients with relapsed rhabdomyosarcoma, Ewing’s sarcoma, osteosarcoma, or non-rhabdo soft tissue sarcoma are uniformly estimated to be less than 30%. Although many salvage regimens have been published, there is little consensus on the optimal approach to systemic or local therapy in these patients. And with novel agents arriving into oncologists’ armamentarium on a frequent basis, it can be confusing to decide which available “mibs, mabs, and nibs” may have benefit and when referral for early phase therapy is appropriate. In this workshop, our goal is to review available published data regarding the management of recurrent sarcoma, discuss the best way to implement these therapies, and explore which emerging approaches have the most potential for the future.

Recurrent Soft Tissue  
Bhuvana Setty, MD

Recurrent Bone Tumors  
Patrick Leahey, MD

Panel  
Abha Gupta, MD MSc FRCPC; Sheri L. Spunt, MD

5:45–7:45 pm  
Symposia

(S01) Updates in Lymphatic Anomalies for the Hematologist/Oncologist  
Moderator: Cameron Trenor, MD  
The role of pediatric hematologists/oncologists (PHOs) in the care of vascular anomalies is rapidly expanding, and lymphatic anomalies are a particularly challenging subset of these patients. In most programs, PHO trainees have little exposure to lymphatic anomalies. Limitations of procedures and recent reports of successful medical therapies for lymphatic disorders have led to more frequent consultation in our specialty. In this symposium, we will review lymphangiogenesis and available animal models, new data from whole-exome analysis of lesional tissue, updated classification systems, when to employ medical therapies, and results from a phase 2 study of sirolimus. Participants will gain a renewed appreciation of this rapidly evolving field and leave better prepared for consultation and delivery of medical therapies.

Basics of Lymphangiogenesis and Animal Models of Diseases  
Michael Dellinger, PhD

Updated Classification System for Lymphatic Anomalies  
Adrienne M. Hammill, MD PhD

Insights from Whole-Exome Analysis of Lymphatic Disorders  
Matthew Warman, MD

High-Risk Lymphatic Tumors and Malformations—When to Treat  
Cameron Trenor, MD

Sirolimus in Vascular Anomalies: Phase 2 Trial Results  
Denise M. Adams, MD

(S02) Sickle Cell Disease—Saving the Brain and Treating the Pain  
Moderators: Emily Reihm Meier, MD; Michael Callaghan, MD  
The most common complication of sickle cell disease is vaso-occlusive crisis (VOC), while silent cerebral infarcts (SCI) are the most common cause of neurologic damage. Improvements in the management of both complications are urgently needed. The Silent Infarct Transfusion (SIT) trial, the first randomized trial to evaluate treatment strategies for SCI, and the phase 2 study of GMI-1070 (a pan-selectin inhibitor) for treatment of acute VOC were recently completed and will provide new information about the appropriate management for these common sickle cell complications. Despite chronic monthly blood transfusions, many patients who have had an overt stroke will have progressive neurologic damage and vasculopathy. Evidence is lacking regarding the best management of this progressive disease and management decisions are often based on the experience and expertise of multiple specialists (neurologists, neurosurgeons, hematologists). A multisubspecialty panel will discuss management options for commonly encountered neuroradiologic findings of pediatric sickle cell disease.

Introduction  
Michael Callaghan, MD

Results from the Silent Infarct Transfusion Trial  
Michael R. DeBaun, MD MPH

Treating the Pain with GMI-1070  
Timothy L. McCavit, MD

Saving the Brain with a Sickle Cell Neuroradiology Conference  
Jessica L. Carpenter, MD; Monica L. Hulbert, MD; Sepideh Amin-Hanjani, MD

Neuroradiology  
Delilah Burrowes, MD

7:45–9:15 pm  
Corporate Forum Dinner Symposium*  
Division Directors’ Meeting  
Advance registration is required.

*For more information on corporate forum symposia, see page 19.
Thursday, May 15
8–9:30am
Concurrent Workshops

(W05) Missed Opportunities for Scholarship in Education
Rima F. Jubran, MD MPH; Jennifer C. Kesselheim, MD MEd; James L. Harper, MD
Academic pediatric hematologists/oncologists committed to the teaching missions of their institutions frequently develop educational interventions as part of their professional roles. Too often, these physicians miss opportunities to use their educational efforts to enhance their academic portfolios. Because scholarship in education is an established mechanism for academic achievement, we offer a workshop that will provide tools for practicing clinicians to formally study the impact of their educational interventions, seek peer-reviewed publication for their work in education, and disseminate their accomplishments in a scholarly fashion. Using these strategies, participants will learn how to gain academic “credit” for the work they are already doing in education.

(W06) Walking the Line: Ethical Decision Making with Families at the Fringes
Liza Johnson, MD MPH; Deena Levine, MD; Justin N. Baker, MD
Medical decision making in the United States has moved from a paternalistic physician-driven process to a patient-driven, autonomy-based standard. During the past 10 years, the pendulum has shifted to a balanced meet-in-the-middle approach commonly defined as shared decision making. Families who listen to all medical options and select the recommended (standard) option are often perceived to be equal partners. Families who refuse medical recommendations or demand medically inappropriate interventions exist outside of the norm and challenge the communication and shared decision-making skills of clinicians. In this interactive workshop, we will review general concepts of ethical decision making in the context of pediatric hematology/oncology as well as discuss difficult end-of-life decision making. Participants will learn the ethical principles used when evaluating possible medical neglect or demands for futile or medically inappropriate care. The workshop will provide participants with strategies for communicating with families perceived to be “unreasonable” or “at the fringes.”

(W07) Decreasing Time to Antibiotic Delivery in Febrile Neutropenic Patients Through Quality Improvement Methods in Your Home Institution
Moderator: Christopher E. Dandoy, MD
Deficits exist in the quality of care that is delivered to pediatric patients. Administration of antibiotics in neutropenic patients involves collaboration and coordination between multiple teams throughout the healthcare delivery system. Unfortunately, these delivery systems often work imperfectly. This workshop will be open to those wanting to learn the basics of quality improvement and use these tools to improve the time-to-antibiotic delivery in febrile neutropenic patients in their home institution. Attendees will be required to obtain preliminary data prior to the workshop that will be used to understand their individual delivery system. In the seminar, they will learn the fundamental principles of the model for improvement, receive an introduction to the ASPHO time-to-antibiotic module, and apply these tools to measure and decrease time to antibiotics in febrile neutropenic patients in their home institution.

Overview of Quality Improvement Concepts and State of Quality Improvement in Pediatric Hematology/Oncology
Christopher E. Dandoy, MD

Time to Antibiotics in Febrile Neutropenic Patients: The Cincinnati Children’s Hospital Experience
Evaline A. Alessandrini, MD MSCE

Introduction to the ASPHO Time-to-Antibiotic Initiative
Joanne M. Hilden, MD
9:45 am–Noon

**Presidential Symposium and State of the Society**

**(S03) The Future of Pediatric Hematology**  
Moderator: A. Kim Ritchey, MD

After 20 years of clinical trials, the first gene therapy products have been licensed. Clinical trials now underway address a variety of diseases managed by hematologists, including thalassemia and hemophilia. How quickly are gene therapies for these diseases likely to become therapeutic options, and how will their availability change the management of these disorders? What are the side effects and complications likely to be? Which patients will be the best candidates for these treatments? This session will address these questions by surveying current developments in the field. There is an explosion of preclinical and phase 1/phase 2 studies with new biologic approaches to hemoglobinopathies. Understanding the complex pathophysiology of the hemoglobinopathies will help to guide us into the future of treatment for these disorders. In addition, stem cell transplantation is playing a greater role in the management of patients with sickle cell disease today. What role will transplantation play in the routine care of sickle cell patients in the future? Although the specific mutations in the human adult β-globin gene in sickle cell anemia and β-thalassemia have been known for many years, no mechanism-based management of these disorders has been developed. The level of fetal hemoglobin is a powerful modifier of the severity of both sickle cell disease and β-thalassemia. Reactivation of HbF in adults has been long proposed as an approach to these conditions. Genome-wide association studies provided the first clues to the specific regulators of HbF in humans. This talk will review recent progress in this field and the prominent role of the repressor BCL11A in control of HbF. Implications for potential therapeutic approaches will be presented.

**Gene Therapy and Hematology—How Will Our Field Be Affected?**  
Katherine A. High, MD

**The Complex Pathophysiology of the Hemoglobinopathies: Guiding Us to Innovative Therapy**  
Elliott P. Vichinsky, MD

**Reawakening Fetal Hemoglobin: New Opportunities and Challenges**  
Stuart H. Orkin, MD

12:15–1:15 pm

**(L01) Early Career Roundtable Luncheon**  
Moderator: Sarah Vaiselbuh, MD

Fellows and junior faculty will have an opportunity to meet with a leader in the field of pediatric hematology/oncology. Two experts in the following fields will be available for career discussions: clinical research-hematology, clinical research-oncology, basic science/translational research, and clinician/educator. A special interest table will be available for issues specific to foreign medical graduates. The purpose of this luncheon is to allow fellows and junior faculty to discuss issues one on one with leaders in the field or ask questions related to career development in a small-group setting. One to two discussion leaders will be placed at each luncheon table. After 30 minutes of discussion, the YI participants will be invited to switch to a different table for further discussion.

**Foreign Medical Graduates**  
Sarah Vaiselbuh, MD; Sinisa Dovat, MD PhD

**Basic Science/Translational Research**  
Douglas K. Graham, MD PhD; Daniel S. Wechsler, MD PhD; Kathleen M. Sakanoto, MD PhD

**Clinician Educator**  
Caroline A. Hastings, MD; Joanne M. Hilden, MD

**Clinical Research–Hematology**  
Jeffrey M. Lipton, MD PhD; George R. Buchanan, MD

**Clinical Research–Oncology**  
William G. Woods, MD; Mark P. Atlas, MD

1:45–3:45 pm

**Symposia**

**(S04) Tumor Heterogeneity: Biology and Therapy**  
Moderators: Patrick Brown, MD; Alex Kentsis, MD PhD

Although cancers are caused by distinct genetic mutations that lead to clonal proliferation of cells, clinical disease is almost always heterogeneous. This heterogeneity of tumors with respect to the biological pathways that drive them is increasingly being recognized as the major cause of therapy resistance and disease relapse. As a result, there is an emerging need to understand the biological basis of tumor heterogeneity and develop paradigms of treatment that overcome it.

**Beyond Genomics: Nongenetic Causes of Heterogeneity in Pediatric Leukemia**  
Jeffrey Magee, MD PhD

**Cellular Origins of Rhabdomyosarcoma: Implications for Tumor Heterogeneity**  
Simone Hettmer, MD
Tumor Metastasis: Lessons Learned from Medulloblastoma
Tobey J. Macdonald, MD

(S05) When Less Is More: Update on Reduced Intensity/Nonmyeloablative Stem Cell Transplant Conditioning Regimens in Malignant and Nonmalignant Disorders
Moderators: Valerie Brown, MD PhD; Roger H. Giller, MD
Pediatric patients with malignant as well as nonmalignant disorders have benefited greatly from allogeneic hematopoietic stem cell transplantation (HSCT). As the availability of alternative donor sources has expanded, the indications for undergoing allogeneic HSCT have expanded as well, particularly for nonmalignant disorders. However, the transplant-related morbidity and mortality (TRM) associated with myeloablative pretransplant conditioning regimens has historically been unacceptable for patients with nonmalignant disorders as well as for patients with hematologic malignancies whose prior treatment has resulted in significant comorbidities. Reduced intensity (RI) and nonmyeloablative (NMA) conditioning regimens offer these previously ineligible patients the opportunity to undergo curative allogeneic HSCT. To make optimal treatment decisions for these patients, pediatric hematologists/oncologists need to be knowledgeable of risks and benefits of using RI/NMA pretransplant conditioning regimens.

Introduction Comparing Myeloablative vs. Nonmyeloablative vs. Reduced Intensity Conditioning (RIC) Regimens for Allogeneic HSCT
Valerie Brown, MD PhD; Roger H. Giller, MD

Friday, May 16

7 am–4:45 pm
Early Career Coffee Corner

7:30–9 am
Diversity Special Interest Group
Career Development and Increasing Diversity in Pediatric Hematology/Oncology
Cochairs: Sarah Vaiselbuh, MD; Theodore Johnson, MD PhD
The Diversity Special Interest Group will offer an interactive workshop focused on identifying barriers to career advancement for underrepresented individuals and groups, and developing practical strategies to overcome these barriers. This workshop will be open to all ASPHO annual meeting attendees, but will require advance registration.

ASPHO Annual Meeting  Educational Program

The Role of RIC in Nonmalignant Disorders
Parinda A. Mehta, MD

The Role of RIC in Hematologic Malignancies
Mitchell S. Cairo, MD

Novel Agents Such as Treosulfan Used in Pretransplant Conditioning Regimens
Lauri M. Burrroughs, MD

4–5 pm
Concurrent Platform Sessions

5:15–5:45 pm
Plenary Platform Session

5:45–6:45 pm
Author-Attended Poster Session A
Odd-numbered posters

5:45–7:30 pm
Grand Opening Reception with Exhibits and Posters

7:30–9 pm
Corporate Forum Dinner Symposium*

*For more information on corporate forum symposia, see page 19.
9–11 am
Symposia
(S06) Genomics and Personalized Medicine in Childhood Cancer
Moderator: Sarah Vaiselbuh, MD
Childhood cancers more and more are being identified by their genomic signatures, which allows for high-precision classification of the disease. The precise analysis and understanding of what drives the cancer allows for future development of personalized medicine in pediatric cancer. A basic understanding of genomics and its clinical implications are necessary to educate pediatric hematology/oncology physicians. A particular focus will be the impact of this genomic data on current clinical practice and its therapeutic implications. Discussion will center on how to develop a coordinated effort to integrate the vast amount of data generated from diverse sources for clinical application and evidenced-based protocols to drive clinical decisions in the treatment of pediatric cancer. The practice gap from theoretical research data to practical translation is bridged in this symposium.

Integrated Genomic Approach to Identify New Targets in Ewing Sarcoma
Sarah Vaiselbuh, MD

Clinical Relevance of Genomics and Childhood Cancer
Katherine A. Janeway, MD MMSc

Genomic Landscape in Childhood ALL and Therapeutic Implications
William Carroll, MD

From Genome to Epigenome and Experimental Cancer Therapy
Sinisa Dovat, MD PhD

Integrated Genomic Approach to Identify New Targets in Ewing
Kimberly Stegmaier, MD

(S07) Update on Coagulation and Platelet Testing
Moderators: Michael Wang, MD; Mindy Simpson, MD
Coagulation and platelet function abnormalities remain an important component of pediatric inpatient, outpatient, and consultation services. Knowledge and understanding of recent advances in testing methodologies will be beneficial to all ASPHO members and will aid in the diagnosis and management of pediatric hematology patients.

Advances in VWD Pathophysiology and Diagnosis
Veronica H. Flood, MD

Simultaneous Thrombin and Plasmin Generation Assays for Assessment of Hemostasis
Mindy Simpson, MD

Thromboelastography in the Diagnosis and Treatment of Bleeding Disorders
Guy Young, MD

Microfluidics for Hemostatic Testing Under Physiologic Conditions
Jorge DiPaola, MD

11–11:30 am
Break in Exhibit Hall
Sponsored by St. Jude Children’s Research Hospital.

11:30 am–1 pm
Concurrent Workshops
(W08) What’s All the Buzz About Targeted Immunotherapies for B-Cell Malignancies?
Moderator: Susan R. Rheingold, MD
Despite great progress in curing childhood acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), survival after relapse remains poor. Further intensifications of cytotoxic therapy, improvements in bone marrow transplant, and better supportive care have not led to improved salvage rates. Targeted immune therapies, the most promising new therapeutic advance in pediatric lymphoid cancers, have been studied in phase 1 trials and are moving into phase 2/3 studies nationally. In this session, we will explore three avenues of targeted immune therapy for B-cell ALL and NHL: the monoclonal antibody-based immunotoxin moxetumomab pasudotox (HA22) targeted against CD-22, the bispecific CD-3/CD-19 antibody (blinatumomab, MT-103) for B-cell malignancies, and adoptive immunotherapy with patient-specific T cells engineered to eradicate malignant CD-19+ B cells (CTL019). Currently, all are available in pediatric trials and have the potential to revolutionize the way we treat both de novo and refractory hematologic B-cell malignancies.

CD 22 Targeted Therapy for B-Cell Malignancies
Alan Wayne, MD

CD 19 Targeted Therapy for B-Cell Malignancies
Lia Gore, MD

Engineering Patient T Cells to Attack B-Cell Malignancies
Stephan A. Grupp, MD PhD
(W09) Neonatal Thrombosis: An Insight on Development, Management, and Outcomes
Moderator: Anthony K. Chan, MBBS FRCPC
Neonatal thrombosis has evolved greatly in the past 20 years or so, however, many questions remain. The workshop will explore the following:
1. Interpretation of laboratory values in premature and term neonates is a challenge.
2. An update on current understanding of developmental hemostasis paralleled with case-based discussion on interpretation of results will help to address this challenge. Given the heterogeneity in the clinical condition of neonates with thrombosis, it is difficult to establish strict guidelines for dosing and duration of anticoagulation therapy.
3. A discussion of cases will highlight appropriate management of neonatal thrombosis based on clinical context. Long-term complications of venous thromboembolism in children include post-thrombotic syndrome with a prevalence of 26% based on a recent systematic review.
4. A presentation on post-thrombotic syndrome and its recently standardized definition will help to raise awareness and guide investigation and management of this important complication.

Developmental Hemostasis: A Focus on Interpreting Laboratory Values without Local Laboratory Reference Ranges
Bryce A. Kerlin, MD

Anticoagulation in Neonates—Dosing and Duration
Anthony K. Chan, MBBS FRCPC

Post-Thrombotic Syndrome—More Prevalent Than We Think
Leonardo R. Brandao, MD MSc

Where Are We Headed? Relevant Research Questions for the Future in Neonatal Thrombosis
Anthony K. Chan, MBBS FRCPC

(W10) Late Career Transitions in Pediatric Hematology/Oncology
Moderators: Kathleen M. Sakamoto, MD PhD; Patrick A. Zweidler-McKay, MD PhD
The focus of the 1.5-hour interactive workshop, Late Career Transitions in Pediatric Hematology/Oncology, will be to address transition and succession, which was one of the challenges identified by a previous ASPHO workshop held in 2008. The workshop in 2008 resulted in the article “Defining and Managing Career Challenges for Mid-Career and Senior Stage Pediatric Hematologists/Oncologists” (Fruge et al. Pediatric Blood and Cancer, 55: 1180-84, 2010). Since the workshop in 2008 and the publication, there has not been a follow-up workshop to address the difficulties for mid- to late-career faculty. In addition, although there has been significant focus on the early career (formerly young investigator) group, there has been little attention on ASPHO members in the later stages of their career.

This workshop will address the needs of this group as well as provide anticipatory guidance for early and mid-career pediatric hematologist/oncologists.

Introduction
Kathleen M. Sakamoto, MD PhD

New Beginnings: Continuing the Life Journey
Philip A. Pizzo, MD

Defining and Managing Career Challenges for Mid-Career and Senior Stage Pediatric Hematologists/Oncologists
Ernest Frugé, PhD

Panel Discussion on Late-Career Transitions
Patrick A. Zweidler-McKay, MD PhD

1–2 pm
Author-Attended Poster Session B
Even-numbered posters

1–2:30 pm
Lunch in Exhibit Hall
Exhibits and Posters

“Workshops are a good opportunity for review.”
—2013 Meeting Attendee

www.asphomeeting.org
2:30–4:30 pm

**Symposia**

**(S08) Leadership Skills for Early Career Professionals**

*Moderator: Sarah Vaiselbuh, MD*

Leadership constantly presents challenges both to the leader’s abilities and to the leader as a person. Change brings challenges, and these challenges can convince an early career (EC) provider he or she is not cut out to be a leader. How effectively we learn to handle those challenges will define us as leaders. Challenges present as three types: from the outside (people, problems, obstacles), from within (personality, emotions, experience), or situationally. Challenges are stepping stones to personal growth and an invitation to be tested and pass the test while improving the process.

Few of us were born with leadership skills; most of us have to climb the mountain by recognizing, learning from, and rising to the challenges of leadership.

The goal of this workshop is to provide tools to start developing as a leader and to successfully mountain climb while addressing each of the three leadership challenges.

**Leading Change**

*Sarah Vaiselbuh, MD*

**Self-Awareness: The Leader Within**

*Joanne M. Hilden, MD*

**Management Is Not Leadership. Leadership Is Service**

*Julie A. Panepinto, MD MSPH*

**(S09) Bone Health in Pediatric Hematology/Oncology**

*Moderator: Michael Recht, MD PhD*

As children with inherited hematologic conditions and long-term survivors of cancer live longer, the pediatric hematologist/oncologist must be concerned with the morbidity of the underlying condition as well as that of the therapy. One such morbidity that has been increasingly identified is the risk of osteopenia and osteoporosis in this patient population. Recent publications have demonstrated a significant incidence of bone disease in those surviving stem cell transplant and leukemia therapy. Likewise, osteopenia and osteoporosis have been identified in children with hemophilia. Recent animal models have suggested that mice genetically engineered to lack factor VIII have significant bone disease, despite the fact that they do not have joint bleeding. This symposium will review bone metabolism as well as showcase work on bone disease and possible interventions in the pediatric hematology/oncology population.

---

**Overview of Bone Health and Metabolism**

*Sogol Mostoufi-Moab, MD MSCE*

**Bone Health in Survivors of Childhood Cancer**

*Susan Lindemulder, MD*

**Bone Health in Children with Congenital Bleeding Disorders**

*Jason Taylor, MD*

**Review of Imaging and Diagnostic Testing**

*John McFadden, MD*

4:45–5:45 pm

**Concurrent Platform Sessions**

6–7:30 pm

**Awards Presentation**

(L02 and L03) Young Investigator Award Presentations

(L04) Frank A. Oski Memorial Lecture

**Distinguished Career Award**

7:30–8:30 pm

**Awards and Networking Reception**

Join us in celebrating the award recipients with a night of networking, live music, appetizers, and beverages.
Saturday, May 17

7–9 am

**L05 Maintenance of Certification (MOC) Learning Session**

Glen Lew, MD; Lakshmanan Krishnamurti, MD; Guy Young, MD; Leo Mascarenhas, MD MS; Jeffrey D. Hord, MD; Amar Gajjar, MD; Robert Liem, MD

This Maintenance of Certification (MOC) Learning Session will feature an American Board of Pediatrics (ABP) Lifelong Learning and Self-Assessment Module; it is intended for those who are enrolled in the MOC process and would like to earn MOC activity points. Learning sessions will be conducted in an interactive group setting and are led by authors or experts in the field of pediatric hematology/oncology.

The 2-hour session will cover the multiple-choice questions in the 2014 Pediatric Hematology-Oncology Self-Assessment. Please bring your laptop (Wi-Fi will be provided) to enter the answers to each question during the session. Topics will include haplo-identical BMT for sickle cell disease, hemophilia inhibitor formation, bortezomib in ALL, observation in low-risk neuroblastoma, immunotherapy for aplastic anemia, medulloblastoma subgroups, hydroxyurea and stroke prevention in sickle cell disease, and chemotherapy for Ewing’s sarcoma.

At the completion of this session, those enrolled in the ABP MOC program will have been able to submit their answers to ABP MOC for scoring to receive 10 MOC Part 2 points and 3 AMA PRA Category 1 Credits™. Enrolled participants can access the module(s) online from the ABP website at www.abp.org. At the conclusion of the session, participants will transfer the answers to their online module and submit the module to ABP for scoring. For additional information about ABP’s MOC program requirements, visit www.abp.org or call the ABP Contact Center at 919.929.0461. Please note that this is not a board review activity; the workshop is designed to facilitate completion of ABP’s Lifelong Learning and Self-Assessment MOC requirement.

**Breakfast is included. Advance registration is required. The registration fee is $50.**

**Palliative Care Special Interest Group**

Chair: Karen Moody, MD

During the first half of this meeting, ASPHO Palliative Care Special Interest Group (SIG) members, and those interested in becoming members, are invited to discuss objectives and strategies for our SIG. Topics will include mentorship, website management, standards of care, and planning for next year.

During the second half of the session, the Palliative Care SIG will be offering a special panel discussion, “Complicated Cases in Pediatric Heme/Onc Palliative Care.” Panel members include Justin Baker, MD; Karen Moody, MD; Veronica Carullo, MD; and Stacey Berg, MD. Palliative care as it applies to pediatric hematology/oncology offers a framework for the pediatric hematologist/oncologist to address some of the most significant challenges when caring for their patients. In this interactive forum, ASPHO members will bring their complicated cases to a panel of palliative care and pain experts to discuss how they would manage issues such as intractable pain, chronic, pain, fear of dying, and family disagreement with regard to care. Cases will be chosen from those submitted by ASPHO members. Audience participation is encouraged.

**Advance registration is required.**

9–10:30 am

**Concurrent Workshops**

(W11) Old Dogs, New Tricks: Demystifying Complementary Medicine

Moderator: Kate A. Mazur, MSN RN CPNP

There continues to be a gap between patients’ use of complementary medicine (CM) and the scientific evidence regarding the safety and efficacy of its practice. Patients with hematologic and oncologic diagnoses increasingly use CMs in conjunction with conventional treatments. Despite its prevalence, many patients fail to disclose CM use to their providers, often due to fears of judgment or because they are not routinely asked about such therapies. Pediatric hematologists’ and oncologists’ general lack of comfort and knowledge of CM is likely the root of this disconnect. Optimal comprehensive cancer and hematology treatment, palliation, and survivorship obligate provider education regarding CM. Increasing providers’ knowledge base will aid in developing an open and nonjudgmental dialogue with their patients to address the potential benefits, limitations, and risks of these therapies. Facilitating these discussions will ultimately demonstrate respect for patients’ health-related beliefs and behaviors, foster mutual trust, and could encourage better compliance with conventional treatments.

**Bringing Evidence to Complementary and Alternative Therapies for Children**

Kara Kelly, MD

**Unnatural Aspects of Natural Medicine: Pearls and Pitfalls in Pediatric Oncology**

BrookeBernhardt, PharmD MS BCOP

**The Role of Mind-Body Therapies in Clinical Practice**

Susan F. Sencer, MD

(W12) Protecting the Future: Fertility Challenges in Oncology Patients

Moderators: Karen E. Effinger, MD MS; Lisa Triche, MSN RN CPNP

Adolescents and young adults (AYAs) with cancer have many unmet healthcare needs, particularly in the realm of fertility preservation. Future fertility is a great concern of many AYA patients and the parents of younger children and should be addressed prior to oncologic diagnoses increasingly use CMs in conjunction with conventional treatments. Despite its prevalence, many patients fail to disclose CM use to their providers, often due to fears of judgment or because they are not routinely asked about such therapies. Pediatric hematologists’ and oncologists’ general lack of comfort and knowledge of CM is likely the root of this disconnect. Optimal comprehensive cancer and hematology treatment, palliation, and survivorship obligate provider education regarding CM. Increasing providers’ knowledge base will aid in developing an open and nonjudgmental dialogue with their patients to address the potential benefits, limitations, and risks of these therapies. Facilitating these discussions will ultimately demonstrate respect for patients’ health-related beliefs and behaviors, foster mutual trust, and could encourage better compliance with conventional treatments.

**Advance registration is required.**
infertility. This interactive workshop will review treatments that affect fertility, fertility preservation options for prepubertal and postpubertal males and females, and future directions in preservation techniques.

**Introduction**

Karen E. Effinger, MD MS; Lisa Triche, MSN RN CPNP

**Fertility of Long-Term Survivors of Childhood Cancer**

Daniel M. Green, MD

**Male Fertility Preservation: Options and Program Development**

Jill P. Ginsberg, MD

**Female Fertility Preservation Options and Strategies for Consults and Collaboration**

Jacqueline S. Jeruss, MD PhD

**Cases for Discussion**

Karen E. Effinger, MD MS

**10:45 am–12:45 pm**

**Symposia**

(S10) Personalized Care for Pediatric Brain Tumors: Fact or Fiction?

Moderator: Donald William Parsons, MD PhD

New insights into the genetics and biology of pediatric brain tumors, combined with the development of novel molecularly targeted cancer therapeutics, offer the promise of personalized cancer care for pediatric neuro-oncology patients. However, significant obstacles remain until selection of a treatment strategy for each child based on the genetic makeup of his or her individual tumor becomes routine in the pediatric neuro-oncology clinic. This symposium will explore these advances and obstacles by presenting examples of clinical trials that utilize state-of-the-art genetic and genomic technologies to characterize the biology of patient tumors and determine the therapeutic strategy for each patient, with a focus on the application of these methods to neuro-oncology.

**Introduction**

Donald William Parsons, MD PhD

**Delivering Molecularly Guided Therapy in Pediatric Brain Tumors**

Giselle Sholler, MD

**Towards Precision Medicine: Lessons from a Pediatric Oncology Pilot**

Rajen Mody, MD

**Moving Medulloblastoma Therapy into the Molecular Age**

Giles Robinson, MD

(S11) Out of Body Experiences: Extracorporeal Therapies in Pediatric Hematology

Moderator: Cameron Trenor, MD

In-depth exposure to extracorporeal therapies such as ventricular assist devices (VAD), extracorporeal membrane oxygenation (ECMO), pheresis procedures involving blood products and hemodialysis often is not emphasized during traditional pediatric hematology/oncology (PHO) training. Thus, PHO providers often lack sufficient expertise about these intensive and highly specialized therapies usually applied to complex and critically ill patients. Patients undergoing extracorporeal therapies represent challenging and not infrequent consults for pediatric hematologists. This symposium will seek to impart a working knowledge of these specialized therapies along with their recent advances and hematologic implications. Better informed interfaces between hematology and cardiology, critical care, transfusion medicine, and nephrology services should lead to improved strategies for minimizing risks associated with extracorporeal therapies, thus enabling provision of the highest quality care.

**Introduction**

Cameron Trenor, MD

**ECMO—Streamlining Anticoagulation to Minimize Risk**

Ravi Thiagarajan, MD

**VADs—Hemorrhagic and Thrombotic Complications**

Leonardo R. Brandao, MD MSc

**Plasma and Blood Cell Pheresis Therapies**

Stella T. Chou, MD

**What the Hematologist Needs to Know About Dialysis**

Anjali Sharathkumar, MD MS

---

**Posters**

The 27th Annual Meeting will feature two author-attended poster sessions. Chosen from a large number of submissions, the posters will represent the best innovations and research in the study and treatment of pediatric hematology/oncology. Poster abstracts selected for presentation at the annual meeting will be published online in a searchable PDF and for online publication in the *Pediatric Blood & Cancer* journal. This will allow registrants to plan their poster viewing in advance of the meeting. The abstracts are scheduled to be available in March 2014. To search and view the abstracts, visit the ASPHO website at www.asphomeeting.org.
Faculty

Denise M. Adams, MD  
Cincinnati Children’s Hospital Medical Center  
Cincinnati, OH

Eva A. Alessandrini, MD  
MSCE  
Cincinnati Children’s Hospital Medical Center  
Cincinnati, OH

Sepideh Amin-Hanjani, MD  
University of Illinois at Chicago  
Chicago, IL

Michael R. DeBaun, MD MPH  
Vanderbilt University  
Nashville, TN

Mark Del Monte, JD  
American Academy of Orthopaedic Surgeons  
Washington, DC

Michael Dellinger, PhD  
UT Southwestern Medical Center  
Dallas, TX

Jorge DiPaola, MD  
University of Colorado Denver  
Aurora, CO

Sinika Dovat, MD PhD  
Pennsylvania State University College of Medicine  
Hershey, PA

Karen E. Ellinger, MD  
Stanford University  
Palo Alto, CA

Veronica H. Flood, MD  
Medical College of Wisconsin  
Milwaukee, WI

Ernest Frugé, PhD  
Baylor College of Medicine  
Houston, TX

Amar Gajjar, MD  
St. Jude Children’s Research Hospital  
Memphis, TN

James R. Gavin III, MD PhD  
Emory University School of Medicine  
Atlanta, GA

Roger H. Giller, MD  
Children’s Hospital Colorado  
Aurora, CO

Jill P. Ginsberg, MD  
Children’s Hospital of Philadelphia  
Philadelphia, PA

Lisa Gore, MD  
University of Colorado Denver  
Aurora, CO

Douglas K. Graham, MD PhD  
University of Colorado Denver  
Aurora, CO

Daniel M. Green, MD  
St. Jude Children’s Research Hospital  
Memphis, TN

Stephan A. Grupp, MD PhD  
Children’s Hospital of Philadelphia  
Philadelphia, PA

Abha Gupta, MD MSc FRCPC  
The Hospital for Sick Children  
Toronto, ON, Canada

Adrienne M. Hammill, MD PhD  
Cincinnati Children’s Hospital Medical Center  
Cincinnati, OH

James L. Harper, MD  
University of Nebraska Medical Center  
Omaha, NE

Caroline A. Hastings, MD  
Children’s Hospital of Oakland  
Oakland, CA

Simone Hettmer, MD  
Boston Children’s Hospital  
Boston, MA

Katherine A. High, MD  
Children’s Hospital of Philadelphia  
Philadelphia, PA

Joanne M. Hilden, MD  
University of Colorado Denver  
Denver, CO

Jeffrey D. Hord, MD  
 Akron Children’s Hospital  
Akron, OH

Monica L. Hubert, MD  
Washington University  
St. Louis, MO

Katherine A. Janeway, MD  
MMSc  
Dana-Farber Cancer Institute  
Boston, MA

Jacqueline S. Jeruss, MD  
Northwestern University  
Chicago, IL

Liza Johnson, MD MPH  
St. Jude Children’s Research Hospital  
Memphis, TN

Theodore Johnson, MD PhD  
Georgia Regents University  
Augusta, GA

Rima F. Jubran, MD MPH  
Children’s Hospital Los Angeles  
Los Angeles, CA

Kara Kelly, MD  
Columbia University Medical Center  
New York, NY

Alex Kentsis, MD PhD  
Memorial Sloan-Kettering Cancer Center  
New York, NY

Bryce A. Kerlin, MD  
National Children’s Hospital  
Columbus, OH

Jennifer Kesselheim, MD MEd  
Brigham and Women’s Hospital  
Boston, MA

Lakshmanan Krishnamurti, MD  
Children’s Hospital of Pittsburgh  
Pittsburgh, PA

Riten Kumar, MD MSce  
Children’s Hospital  
Columbus, OH

Deena Levine, MD  
St. Jude Children’s Research Hospital  
Memphis, TN

Glen Lew, MD  
Alliance Cancer & Blood Disorders Center  
Atlanta, GA

Robert Liem, MD  
Ann & Robert H Lurie Children’s Hospital of Chicago  
Chicago, IL

Susan Lindemulder, MD  
Oregon Health Sciences University  
Portland, OR

Jeffrey M. Lipton, MD PhD  
Emory University Aflac Cancer & Blood Disorders Center  
Atlanta, GA

Naomi L. Luban, MD  
Children’s National Medical Center  
Washington, DC

Thomas E. Macski, MD  
Children’s Hospital of Philadelphia  
Philadelphia, PA

A. Kim Ritchey, MD  
Children’s Hospital of Pittsburgh  
Pittsburgh, PA

Giles Robinson, MD  
St. Jude Children’s Research Hospital  
Memphis, TN

Kathleen M. Sakamoto, MD PhD  
Lucile Packard Children’s Hospital at Stanford  
Palo Alto, CA

Susan F. Sencer, MD  
Children’s Hospital Minnesota  
Minneapolis, MN

Bhuvana Setty, MD  
National Children’s Hospital  
Columbus, OH

Anjali Sharathkumar, MD MS  
Lurie Children’s Hospital of Chicago  
Chicago, IL

Giselle Sholler, MD  
Van Andel Research Institute  
Grand Rapids, MI

Mindy Simpson, MD  
Rush University  
Chicago, IL

Seth J. Smith, MD  
Stanford University School of Medicine  
Palo Alto, CA

Kimberly Stegmaier, MD  
Dana-Farber Cancer Institute  
Boston, MA

Jason Taylor, MD  
Oncology Hematologics University  
Portland, OR

Ravi Thagaparajan, MD  
Boston Children’s Hospital  
Boston, MA

Cameron Treonor, MD  
Boston Children’s Hospital  
Boston, MA

Lisa Triche, MSN RN CNP  
University of Texas MD Anderson Cancer Center  
Houston, TX

Sarah Vaiselbuh, MD  
Children’s Hospital of San Antonio  
San Antonio, TX

Elliott P. Vichinsky, MD  
Children’s Hospital of Oakland  
Oakland, CA

Michael Wang, MD  
University of Colorado Denver  
Aurora, CO

Matthew Warman, MD  
Boston Children’s Hospital  
Boston, MA

Alan Wayne, MD  
Children’s Hospital of Los Angeles  
Los Angeles, CA

Daniel S. Wechsler, MD PhD  
Duke University Medical Center  
Durham, NC

Char Witmer, MD MSce  
Children’s Hospital of Philadelphia  
Philadelphia, PA

William G. Woods, MD  
Emory University Aflac Cancer & Blood Disorders Center  
Atlanta, GA

Nicholas D. Yeager, MD  
Children’s Hospital  
Columbus, OH

Donald L. Yee, MD MS  
Baylor College of Medicine  
Houston, TX

Guy Young, MD  
Children’s Hospital of Los Angeles  
Los Angeles, CA

Patrick A. Zweidler-McKay, MD PhD  
University of Texas MD Anderson Cancer Center  
Houston, TX

18 www.asphomeeting.org
Independently sponsored corporate forum symposia are offered in conjunction with the ASPHO 27th Annual Meeting. The programs have been reviewed and approved by the 2014 ASPHO Program Committee to ensure they are relevant to the audience and do not duplicate the official ASPHO Annual Meeting program.

These satellite symposia are open to 2014 Annual Meeting registrants at no additional charge, though advance registration is required. See the registration details for each symposium below. Seating is limited and available to those responding on a first-come, first-served basis.

**Wednesday May 14**

**7:45–9:15 pm**

**Corporate Forum Dinner Symposium**

**Building on Asparaginase Therapy to Improve Outcomes in Acute Lymphoblastic Leukemia**

Ching-Hon Pui, MD (Chair); Stephen E. Sallan, MD; Additional Speakers TBD

Clinicians must remain informed regarding optimal use of asparaginase therapy and management of adverse events in pediatric patients with acute lymphoblastic leukemia (ALL) to maximize treatment benefit and improve patient care. This symposium, chaired by leukemia expert Ching-Hon Pui, will focus on best practices in asparaginase therapy for pediatric patients with ALL.

This activity will be planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). prIME Oncology is accredited by the ACCME to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Register online for this symposium at www.primeoncology.org/pediatricall2014. There is no fee for attending this symposium, but seating is limited. Preregistration is highly encouraged but does not guarantee seating. We recommend arriving at the symposium location early.

*This symposium is supported by an educational grant from Jazz Pharmaceuticals.*

**Thursday, May 15**

**7:30–9 pm**

**Corporate Forum Dinner Symposium**

**A Clinical Case Debate Forum: Factor-Deficient Children with Intracranial Hemorrhage—Identification, Treatment, Management**

Speakers TBD

Each year, approximately 50,000 people in the United States experience an intracranial hemorrhage (ICH). In children, ICH may be the clinical presenting symptom of an underlying severe coagulation factor deficiency. This symposium, in a debate format, focuses on the management of children with ICH due to congenital factor deficiencies. Please visit us at www.bloodcmecenter.org to learn more about this event.

This activity will be planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM), the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. PIM is accredited by the ACCME to provide continuing medical education for physicians.

PIM designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

There is no registration fee for attending this symposium; however, seating is limited. To register for this symposium, contact Jodi Andrews at jandrews@conceptsinmed.com. Preregistration does not guarantee seating. We do recommend arriving at the symposium location early.

*This symposium is supported through an educational grant from Novo Nordisk.*

---

**Sunshine Act**

The Physician Payment Sunshine Act (Sunshine Act)—Section 6002 of the Patient Protection and Affordable Care Act mandates the disclosure of the National Provider Identifier (NPI) number for any “payment or other transfer of value over $10” given to a physician from any pharmaceutical, device, or biologics manufacturing company. Although final rules are still pending from the Centers for Medicare & Medicaid Services, it seems likely that CME activities will be exempted from reporting, although associated meals will not be exempt. The Sunshine Act, implemented in 2013, requires that electronic disclosures be sent to the U.S. Department of Health & Human Services (DHHS). Associations have been requested to help healthcare firms with this compliance by collecting the NPI numbers of their healthcare provider attendees when such a transfer of value from industry to a physician occurs. To comply with these anticipated rules, ASPHO is collecting the NPI number of its physician conference registrants for reporting purposes. Please note that only industry-supported “transfers of value” (meals, for example) will be collected and reported. Please provide your NPI number where requested on the ASPHO Annual Meeting registration form.
Thursday, May 15
8 am–4 pm  Exhibit and Poster Setup/ Registration
5:45–7:30 pm Grand Opening Reception with Exhibits and Posters

Friday, May 16
8 am–2:30 pm Exhibit Hours
8–9 am Continental Breakfast in Exhibit Hall
11–11:30 am Break in Exhibit Hall, Passport Program Giveaway
1–2:30 pm Lunch in Exhibit Hall
2:30–5 pm Exhibitor Teardown
| 2014 Exhibitors |

ApoPharma Inc  
BTG International Inc.  
Calmoseptine, Inc.  
The Children’s Hospital of Philadelphia  
Cincinnati Children’s Hospital  
Cook Children’s Health Care System  
CSL Behring*  
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center*  
The Gideons International  
Grifols USA  

Jazz Pharmaceuticals, Inc.  
Kedrion Biopharma  
The Pablove Foundation  
Seattle Cancer Care Alliance  
St. Baldrick’s Foundation  
St. Jude Children’s Research Hospital  
The University of Texas MD Anderson Children’s Cancer Hospital*  
Walgreens Infusion Services  

*Passport Program participant list as of 10/17/13

| Passport Program 2014 |  
Win prizes in the Exhibit Hall by visiting the participating booths.

| ASPHO Thanks the Annual Meeting Supporters |

| ASPHO Thanks the Corporate Forum Supporters |
ASPHO is the only organization exclusively for and about pediatric hematology/oncology. ASPHO fosters collaborations to develop optimal treatments for children with blood disorders and cancer.

Why join ASPHO?
When you join ASPHO, you belong to a community of more than 950 professionals who share mutual goals, interests, and commitments related to developing optimal treatments for children with blood disorders and cancer. ASPHO is the only professional organization uniquely dedicated to the professional development and interests of subspecialists in pediatric hematology/oncology.

ASPHO membership provides you with
• a member discount of up to $195 on the annual meeting registration fee
• a monthly subscription to Pediatric Blood & Cancer, the official journal of ASPHO, a source for current, relevant peer-reviewed scientific and clinical research
• a forum for presenting research to colleagues and peers
• connections to a diverse and collaborative network of peers
• a voice for pediatric hematology/oncology policy
• access to state-of-the-art education for the subspecialty
• leadership and mentoring opportunities
• an opportunity to make a difference for your profession, children with blood disorders and cancer, and their families.

Join and save on registration for the annual meeting today! (See the registration form for details.)
ASPHO 2014 Annual Meeting Registration Form
May 14–17, 2014 | Chicago | Palmer House Hilton

Please print. Use a separate form for each registrant. Duplicate as necessary.

Complete Name ___________________________ First Name for Badge ___________________________

Credentials ____________________________________________________ National Provider Identifier (NPI) # ____________________
See page 19 for details.

Facility ___________________________ Facility City/State ___________________________

Preferred Address □ Home □ Office ___________________________ City/State/ZIP ___________________________

Home Phone ___________________________________________ Office Phone ___________________________________________ Fax ___________________________________________

E-mail* (required) □ Home □ Office ___________________________ (FAX) □ Check here if this will be your first ASPHO Meeting.

*You will receive an e-mail confirmation of your registration when it has been processed.

Emergency Contact Name ___________________________ Day Phone ___________________________ Evening Phone ___________________________

To register, make your selections in the boxes below, add the subtotals, and indicate the total amount in Box F.

Conference Registration

<table>
<thead>
<tr>
<th>On or Before</th>
<th>After</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member Rates</td>
<td></td>
</tr>
<tr>
<td>Regular Member</td>
<td>$500</td>
</tr>
<tr>
<td>Allied Member</td>
<td>$295</td>
</tr>
<tr>
<td>Trainee Member</td>
<td>$200</td>
</tr>
<tr>
<td>Emeritus Member</td>
<td>$200</td>
</tr>
</tbody>
</table>

Join & Register Rates (add dues in Box B)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Active Member</td>
<td>$500</td>
</tr>
<tr>
<td>Allied Member</td>
<td>$295</td>
</tr>
<tr>
<td>Trainee Member</td>
<td>$200</td>
</tr>
</tbody>
</table>

Joint ASPHO/PBMTC Rates

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular</td>
<td>$635</td>
</tr>
<tr>
<td>Allied</td>
<td>$385</td>
</tr>
<tr>
<td>Trainee</td>
<td>$230</td>
</tr>
</tbody>
</table>

Nonmember Rates

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonmember</td>
<td>$695</td>
</tr>
<tr>
<td>Allied Nonmember</td>
<td>$390</td>
</tr>
<tr>
<td>Trainee Nonmember</td>
<td>$250</td>
</tr>
</tbody>
</table>

Additional Rates*

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Student</td>
<td>$50</td>
</tr>
<tr>
<td>SIOP Member</td>
<td>$590</td>
</tr>
<tr>
<td>Physician from Developing Country</td>
<td>$210</td>
</tr>
</tbody>
</table>

*Only available by phone, fax, or mail. Verification will be made before registration is processed.

Subtotal A $ ________________

Membership Dues

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Active Member</td>
<td>$365</td>
</tr>
<tr>
<td>Allied Member</td>
<td>$150</td>
</tr>
</tbody>
</table>

Trainee Member

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>First-year fellow</td>
<td>no charge</td>
</tr>
<tr>
<td>Second-year fellow</td>
<td>no charge</td>
</tr>
<tr>
<td>Third-year fellow</td>
<td>no charge</td>
</tr>
<tr>
<td>Fourth-year fellow</td>
<td>$115</td>
</tr>
<tr>
<td>Fifth-year fellow</td>
<td>$115</td>
</tr>
</tbody>
</table>

Subtotal B $ ________________

Total D $ ________________

Session Registration

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, May 14</td>
<td></td>
</tr>
<tr>
<td>2:15–3:45 pm</td>
<td>$100</td>
</tr>
<tr>
<td>5:45–7:45 pm</td>
<td>$50</td>
</tr>
<tr>
<td>Thursday, May 15</td>
<td></td>
</tr>
<tr>
<td>8:30–9:30 am</td>
<td>$150</td>
</tr>
<tr>
<td>1:45–3:45 pm</td>
<td>$200</td>
</tr>
</tbody>
</table>

Optional Event Registration

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, May 14</td>
<td></td>
</tr>
<tr>
<td>8:30 am–12:45 pm</td>
<td>$25</td>
</tr>
<tr>
<td>Thursday, May 15</td>
<td></td>
</tr>
<tr>
<td>12:15–1:30 pm</td>
<td>$25</td>
</tr>
<tr>
<td>Friday, May 16</td>
<td></td>
</tr>
<tr>
<td>7:30–9:30 am</td>
<td>$25</td>
</tr>
</tbody>
</table>

Pay online at www.asphomeeting.org

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional</td>
<td></td>
</tr>
<tr>
<td>Fee</td>
<td></td>
</tr>
<tr>
<td>$50</td>
<td></td>
</tr>
</tbody>
</table>

Subtotal E $ ________________

Total F $ ________________

Payment

All funds must be submitted in U.S. dollars.

Visa □ MasterCard □ Discover □ American Express □ Check

If payment does not accompany this form, your registration will not be processed.

* Make checks payable to ASPHO. Checks not in U.S. funds will be returned.

* A charge of $50 will apply to checks returned for insufficient funds.

* If reimbiling of a credit card charge is necessary, a $75 processing fee will be charged.

* I authorize ASPHO to charge the below-listed credit card an amount reasonably deemed by ASPHO to be accurate and appropriate.

Account number ___________________________ Exp. date ___________________________

Cardholder’s name (print) ___________________________ Signature ___________________________

Photography and Video Disclosure: Photographs and video may be taken of participants in ASPHO’s 2014 Annual Meeting. These are for ASPHO use only and may appear on ASPHO’s website, in printed brochures, or in other promotional materials. Attendee photography grants ASPHO permission and consent for use of this photography and video.

Cancellation Policy: All cancellations must be made in writing. A $100 processing fee will be charged for all cancellations postmarked more than 14 days before the event. No refunds will be made under any circumstances on cancellations postmarked after April 30, 2014. ASPHO reserves the right to substitute faculty or to cancel or reschedule sessions because of low enrollment or other unforeseen circumstances. If ASPHO must cancel the entire meeting, registrants will receive a full credit or refund of their paid registration fee. No refunds can be made for lodging, airfare, or any other expenses related to attending the meeting.

4 Easy Ways to Register

Mail ASPHO Meeting, PO Box 31756
Chicago, IL 60631
Fax 866.585.0477
Online www.asphomeeting.org

*credit card payment only

Photography and Video Disclosure: Photographs and video may be taken of participants in ASPHO’s 2014 Annual Meeting. These are for ASPHO use only and may appear on ASPHO’s website, in printed brochures, or in other promotional materials. Attendee

registration grants ASPHO permission and consent for use of this
graphy and video.

Cancellation Policy: All cancellations must be made in writing. A $100 processing fee will be charged for all cancellations postmarked more than 14 days before the event. No refunds will be made under any circumstances on cancellations postmarked after April 30, 2014. ASPHO reserves the right to substitute faculty or to cancel or reschedule sessions because of low enrollment or other unforeseen circumstances. If ASPHO must cancel the entire meeting, registrants will receive a full credit or refund of their paid registration fee. No refunds can be made for lodging, airfare, or any other expenses related to attending the meeting.
Reasons to Attend the
27th Annual ASPHO Meeting
May 14–17, 2014 | Chicago | Palmer House Hilton

• Learn about emerging therapies and research in pediatric hematology/oncology.
• Receive up to **23.25 hours** of CME credit.
• Hear about the future of pediatric hematology/oncology.
• Network with a diverse and experienced faculty.
• Visit **50 exhibitors** displaying their products and innovations.
• Enjoy all Chicago has to offer with fellow ASPHO members.

www.asphomeeting.org